ReviewJournal of fungi (Basel, Switzerland)2021
Ibrexafungerp: A First-in-Class Oral Triterpenoid Glucan Synthase Inhibitor.
Review in Journal of fungi (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed.
- Safety, tolerability, and pharmacokinetics of ibrexafungerp in healthy Chinese subjects: a randomized, double-blind, placebo-controlled phase 1 trial.Antimicrobial agents and chemotherapy · 2023Trial
- Invasive aspergillosis in autoimmune inflammatory rheumatic diseases: epidemiology, risk factors, diagnosis, management and challenges.Annals of medicine · 2026Review
- The urgent and challenging superbug fungus Candidozyma auris (formerly Candida auris): a comprehensive review.Antonie van Leeuwenhoek · 2026Review
- Green spectrofluorimetric determination of Ibrexafungerp using NBD-Cl derivatization.Scientific reports · 2026Article
- Inhibition mechanism of the fungal β-1,3-glucan synthases by triterpenoid antifungal drugs.Nature communications · 2026Article
- The Upcoming Antifungal Drugs in Clinical Development for the Treatment of Invasive Candidiasis.Infection and drug resistance · 2026Review
- Molecular mechanisms drivingFrontiers in molecular biosciences · 2026Review
- Novel Drug Delivery Systems for the Management of Vulvovaginal Candidiasis: Enhancing Therapeutic Efficacy.Current pharmaceutical design · 2026Review
- Molecular mechanisms, pathogenesis and therapeutic advances ofFrontiers in cellular and infection microbiology · 2026Review
- StudyingPharmaceuticals (Basel, Switzerland) · 2025Review
- Review
- Drug Discovery and Repurposing forJournal of fungi (Basel, Switzerland) · 2025Review
- Revealing structure and shaping priorities in plant and fungal cell wall architecture via solid-state NMR.Cell surface (Amsterdam, Netherlands) · 2025Review
- Assessing the vulnerability of Candida colonization through social determinants of health among college students in Puebla, Mexico.Journal of health, population, and nutrition · 2025Article
- Breaking down the wall: Solid-state NMR illuminates how fungi build and remodel diverse cell walls.PLoS pathogens · 2025Article
- Ibrexafungerp: Mechanism of Action, Clinical, and Translational Science.Clinical and translational science · 2025Review
- A Comprehensive Overview ofJournal of fungi (Basel, Switzerland) · 2025Review
- Next-generation antifungal drugs: Mechanisms, efficacy, and clinical prospects.Acta pharmaceutica Sinica. B · 2025Review
- Trichosporon and Antifungal Resistance: Current Knowledge and Gaps.Mycopathologia · 2025Review
- Antibiofilm activity of manogepix, ibrexafungerp, amphotericin B, rezafungin, and caspofungin againstAntimicrobial agents and chemotherapy · 2025Article
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ibrexafungerp (formerly SCY-078 or MK-3118) is a first-in-class triterpenoid antifungal or "fungerp" that inhibits biosynthesis of β-(1,3)-D-glucan in the fungal cell wall, a mechanism of action similar to that of echinocandins. Distinguishing characteristics of ibrexafungerp include oral bioavailability, a favourable safety profile, few drug-drug interactions, good tissue penetration, increased activity at low pH and activity against multi-drug resistant isolates including
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.